Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apixaban Study Halted - But It May Not Cause Much Damage To The Program

This article was originally published in The Pink Sheet Daily

Executive Summary

The APPRAISE-2 trial was stopped due to excess bleeding. But the study tested the drug as an add-on treatment in a high-risk population and in a marginal indication for the anticoagulant.

You may also be interested in...



Final APPRAISE-al: Trial Report Argues Against Anticoagulant/Antiplatelet Combos In ACS

NEJM article points to much higher bleeding with no compensatory efficacy in failed APPRAISE-2 add-on trial with apixaban.

Final APPRAISE-al: Trial Report Argues Against Anticoagulant/Antiplatelet Combos In ACS

NEJM article points to much higher bleeding with no compensatory efficacy in failed APPRAISE-2 add-on trial with apixaban.

Bayer/J&J Attempt At New Lands For Xarelto Backfires With MAGELLAN

Ability of novel anticoagulants to capture an extra indication in acutely ill patients currently treated with blockbuster Lovenox is now in doubt.

Related Content

Topics

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel